

Catalog: TA302879


## Name:Goat Polyclonal Antibody against FOXL2 Product Data Sheet - ANTIBODY

Components:	<ul> <li>Goat Polyclonal Antibody against FOXL2 (TA302879)</li> </ul>
	<ul> <li>1 vial of 20ug myc-DDK tagged FOXL2 HEK293T over-expression lysate lyophilized in RIPA buffer (LC411500). (Reconsitute into 20ul of 1x SDS sample buffer before loading; load 5ul per lane as WB control or as desired)</li> </ul>
Amount:	100ug
Immunogen:	Peptide with sequence C-DSKTGALHSRLDL, from the C Terminus of the protein sequence according to NP_075555.
Host:	Goat
Isotype:	Goat IgG
Species Reactivity:	Human, Mouse
Guaranteed Applications:	WB, IHC
Suggested Dilutions:	ELISA: 1:32,000. WB: 0.5-1.5ug/ml.
Concentration:	0.5 mg/ml
Buffer:	Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.
Purification:	Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. Aliquot and store at -20°C. Minimize freezing and thawing.
Storage Condition:	Shipped at -20C. Upon delivery store at -20C. Dilute in PBS (pH7.3) if necessary. Stable for 12 months from date of receipt. Avoid repeated freeze-thaws.
Target	
Target Name:	Homo sapiens forkhead box L2 (FOXL2)
Alternative Name:	BPES; BPES1; PFRK; PINTO; POF3
Database Link:	NP_075555
Function:	Defects in FOXL2 are a cause of blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES)

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. © 2014 OriGene Technologies, Inc. 9620 Medical Center Dr., Suite 200, Rockville, MD 20850 [MIM:110100]; also known as blepharophimosis syndrome. It is an autosomal dominant disorder characterized by eyelid dysplasia, small palpebral fissures, drooping eyelids and a skin fold running inward and upward from the lower lid. In type I BPSE (BPES1) eyelid abnormalities are associated with female infertility. Affected females show an ovarian deficit due to primary amenorrhea or to premature ovarian failure (POF). In type II BPSE (BPES2) affected individuals show only the eyelid defects. There is a mutational hotspot in the region coding for the poly-Ala domain, since 30% of all mutations in the ORF lead to poly-Ala expansions, resulting mainly in BPES type II.

## **Validation Data**





TA302879 (2ug/ml) staining of paraffin embedded Human Ovary. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.

\* More validation images may be available on our website: <u>http://www.origene.com/antibody/TA302879.aspx</u>